Immuneering (IMRX) Enterprise Value: 2020-2024
Historic Enterprise Value for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to $68.3 million.
- Immuneering's Enterprise Value fell 47.23% to $68.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $68.3 million, marking a year-over-year increase of 140.59%. This contributed to the annual value of $68.3 million for FY2024, which is 47.23% down from last year.
- According to the latest figures from Q4 2024, Immuneering's Enterprise Value is $68.3 million, which was up 194.71% from $23.2 million recorded in Q3 2024.
- In the past 5 years, Immuneering's Enterprise Value ranged from a high of $539.2 million in Q3 2021 and a low of -$50.2 million during Q2 2021.
- For the 3-year period, Immuneering's Enterprise Value averaged around $85.3 million, with its median value being $50.6 million (2022).
- As far as peak fluctuations go, Immuneering's Enterprise Value skyrocketed by 1,181.12% in 2023, and later tumbled by 111.61% in 2024.
- Quarterly analysis of 5 years shows Immuneering's Enterprise Value stood at -$37.1 million in 2020, then skyrocketed by 828.66% to $270.3 million in 2021, then crashed by 91.66% to $22.5 million in 2022, then spiked by 474.42% to $129.5 million in 2023, then tumbled by 47.23% to $68.3 million in 2024.
- Its Enterprise Value stands at $68.3 million for Q4 2024, versus $23.2 million for Q3 2024 and -$21.8 million for Q2 2024.